AIM ImmunoTech is trading 11.6% up in pre-market at $0.25 after closing at $0.22 on August 14, 2026, with no clear company-specific catalyst identified.
- Recent developments include the August 10 second-quarter report and August 3 DURIPANC milestone.
- Broader sentiment is modestly supportive, with the Nasdaq Composite up 0.52% and cryptocurrencies also higher.
- Confidence is low because available coverage does not directly link the move to new company news.